[go: up one dir, main page]

HK1220466A1 - 愛帕琳融合蛋白和其用途 - Google Patents

愛帕琳融合蛋白和其用途

Info

Publication number
HK1220466A1
HK1220466A1 HK16108446.5A HK16108446A HK1220466A1 HK 1220466 A1 HK1220466 A1 HK 1220466A1 HK 16108446 A HK16108446 A HK 16108446A HK 1220466 A1 HK1220466 A1 HK 1220466A1
Authority
HK
Hong Kong
Prior art keywords
fusion proteins
apelin fusion
apelin
proteins
fusion
Prior art date
Application number
HK16108446.5A
Other languages
English (en)
Inventor
Panayiotis Stevis
Jesper Gromada
Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1220466A1 publication Critical patent/HK1220466A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
HK16108446.5A 2013-03-14 2016-07-18 愛帕琳融合蛋白和其用途 HK1220466A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786172P 2013-03-14 2013-03-14
US201361906567P 2013-11-20 2013-11-20
PCT/US2014/028384 WO2014152955A1 (en) 2013-03-14 2014-03-14 Apelin fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
HK1220466A1 true HK1220466A1 (zh) 2017-05-05

Family

ID=50680161

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16108446.5A HK1220466A1 (zh) 2013-03-14 2016-07-18 愛帕琳融合蛋白和其用途

Country Status (16)

Country Link
US (3) US9353163B2 (zh)
EP (1) EP2970415B1 (zh)
JP (1) JP6525951B2 (zh)
KR (1) KR20150127596A (zh)
CN (1) CN105026423A (zh)
AU (1) AU2014236451B2 (zh)
BR (1) BR112015020587A2 (zh)
CA (1) CA2904731A1 (zh)
EA (1) EA201591700A1 (zh)
ES (1) ES2708957T3 (zh)
HK (1) HK1220466A1 (zh)
IL (1) IL240587A0 (zh)
MX (1) MX365551B (zh)
SG (1) SG11201506335YA (zh)
WO (1) WO2014152955A1 (zh)
ZA (1) ZA201505927B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015020587A2 (pt) 2013-03-14 2017-10-10 Regeneron Pharma proteínas de fusão de apelina e suas utilizações
PE20160878A1 (es) 2013-07-25 2016-09-08 Novartis Ag Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca
WO2015013169A2 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
WO2015077491A1 (en) 2013-11-20 2015-05-28 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
US10463716B2 (en) 2014-10-13 2019-11-05 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone
WO2016065042A1 (en) * 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
JP6758294B2 (ja) * 2014-12-23 2020-09-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アペリン受容体により媒介される疾患の処置における代謝的に安定なアペリン類似体
CN107106632A (zh) * 2014-12-29 2017-08-29 中央研究院 一种治疗a型流感病毒感染的方法
AU2016209968B2 (en) 2015-01-23 2018-11-29 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2018175383A1 (en) * 2017-03-22 2018-09-27 Research Corporation Technologies, Inc. Engineered stable ch2 polypeptides
CN110678550B (zh) * 2017-03-29 2023-11-14 国立大学法人宫崎大学 长效肾上腺髓质素衍生物
WO2018208625A1 (en) * 2017-05-06 2018-11-15 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
CN109771634A (zh) * 2017-07-11 2019-05-21 南华大学 含有apelin 12环肽的药物组合物及用途
CN111032689B (zh) * 2017-08-24 2024-02-27 凡恩世制药(北京)有限公司 抗爱帕琳肽抗体及其用途
GB201805675D0 (en) 2018-04-05 2018-05-23 Davenport Anthony Peter Compounds For Use As Apelin Receptor Antagonists
CN119613548A (zh) * 2018-06-13 2025-03-14 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
WO2021263128A1 (en) * 2020-06-25 2021-12-30 Gliknik Inc. Ace2-fc fusion proteins and methods of use
CN112546198B (zh) * 2020-12-17 2022-03-25 温州医科大学慈溪生物医药研究院 一种用于治疗脑中风和急性脑梗的药物组合物
CN113648418B (zh) * 2021-05-08 2022-08-05 南方医科大学 Apelin-APJ抑制剂在制备治疗血睾屏障损伤药物中的应用
WO2024072637A2 (en) 2022-09-30 2024-04-04 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
EP1040189B1 (en) 1997-12-24 2008-01-09 Takeda Pharmaceutical Company Limited Polypeptides, their production and use
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003514552A (ja) * 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
AU2001296023A1 (en) * 2000-10-30 2002-05-15 Takeda Chemical Industries Ltd. Process for producing peptide
US6919183B2 (en) 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
DE602004027798D1 (de) 2003-03-12 2010-08-05 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7450586B2 (en) * 2003-07-22 2008-11-11 Motorola, Inc. Network header compression arrangement
EP1711610A2 (en) * 2004-01-28 2006-10-18 Syntonix Pharmaceuticals, Inc. HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
US20060045880A1 (en) 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
WO2006076736A2 (en) 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
WO2007072980A1 (ja) 2005-12-20 2007-06-28 Takeda Pharmaceutical Company Limited アペリンの新規用途
BRPI0811637B8 (pt) * 2007-05-30 2021-05-25 Genexine Inc proteínas de fusão da imunoglobulina
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
US20120028888A1 (en) 2008-11-04 2012-02-02 Jay Janz Apj receptor compounds
CA2753287A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
US9174428B2 (en) * 2009-08-10 2015-11-03 Corning Incorporated Roll mechanics for enabling printed electronics
EP3202898B1 (en) 2009-11-02 2018-09-26 University of Washington Therapeutic nuclease compositions and methods
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN103052649B (zh) * 2010-07-29 2015-12-16 Xencor公司 具有修改的等电点的抗体
US8881594B2 (en) * 2011-03-06 2014-11-11 Alexander Henry Slocum Tapered spiral bellows pressure sensor
EP3045183B1 (en) * 2011-03-11 2018-07-04 Genzyme Corporation Pegylated apelin and uses thereof
EP2692352A4 (en) 2011-03-31 2014-12-24 Shiseido Co Ltd MEANS FOR SUPPRESSING HEADWALLS
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
US9863605B2 (en) * 2011-11-23 2018-01-09 Quarkstar Llc Light-emitting devices providing asymmetrical propagation of light
CN102516393B (zh) 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN102675470B (zh) * 2012-04-01 2015-06-17 江苏省弗泰生物科技有限公司 SCF-Fc融合蛋白
EP2935311B1 (en) 2012-12-20 2021-03-31 Amgen Inc. Apj receptor agonists and uses thereof
BR112015020587A2 (pt) 2013-03-14 2017-10-10 Regeneron Pharma proteínas de fusão de apelina e suas utilizações
WO2015077491A1 (en) 2013-11-20 2015-05-28 Regeneron Pharmaceuticals, Inc. Aplnr modulators and uses thereof

Also Published As

Publication number Publication date
US9751921B2 (en) 2017-09-05
IL240587A0 (en) 2015-09-24
AU2014236451A1 (en) 2015-10-15
CA2904731A1 (en) 2014-09-25
AU2014236451B2 (en) 2018-08-09
US20160237130A1 (en) 2016-08-18
MX2015011350A (es) 2016-01-15
EA201591700A1 (ru) 2015-12-30
ZA201505927B (en) 2017-03-29
BR112015020587A2 (pt) 2017-10-10
JP6525951B2 (ja) 2019-06-05
WO2014152955A1 (en) 2014-09-25
US20180030099A1 (en) 2018-02-01
SG11201506335YA (en) 2015-09-29
JP2016513733A (ja) 2016-05-16
CN105026423A (zh) 2015-11-04
US20140275489A1 (en) 2014-09-18
ES2708957T3 (es) 2019-04-12
KR20150127596A (ko) 2015-11-17
EP2970415A1 (en) 2016-01-20
US9353163B2 (en) 2016-05-31
EP2970415B1 (en) 2018-12-19
MX365551B (es) 2019-06-07

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
HK1220466A1 (zh) 愛帕琳融合蛋白和其用途
IL261743B (en) and their uses 33–il antibodies against
IL240034A0 (en) Chimeric proteins based on l1–pd and –pd–l2 and their uses
IL261547B (en) Antibodies against pesidine and their uses
IL245040B (en) Antibodies against pdgfr-beta and their uses
IL243974B (en) Antibodies against –prlr and uses
SG10201708143QA (en) Anti-c10orf54 antibodies and uses thereof
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
HK1220903A1 (zh) 軟骨結合型融合蛋白
PT2983704T (pt) Polipéptidos de fusão e vacinas
EP3029071A4 (en) Saxatilin-fc fusion protein and use thereof
AU2013901331A0 (en) Fusion Proteins and Use Thereof